News Image

Exploring NASDAQ:ALKS's growth characteristics.

By Mill Chart

Last update: Feb 28, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into ALKERMES PLC's Growth Metrics.

  • ALKERMES PLC showcases a robust Return on Equity (ROE) of 15.85%, indicating its ability to generate favorable returns for shareholders. This metric underscores the company's efficiency in utilizing its equity capital to generate profits.
  • ALKERMES PLC has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
  • The 1-year revenue growth of ALKERMES PLC (40.56%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
  • ALKERMES PLC has achieved 50.91% growth in its revenue over the previous quarter, signaling positive momentum in its financial performance and potential market opportunities.
  • With a favorable trend in its operating margin over the past year, ALKERMES PLC demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
  • ALKERMES PLC has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
  • The EPS of ALKERMES PLC has exhibited growth from one quarter to another (Q2Q), with a 3.0K% increase. This underscores the company's ability to generate higher earnings and improve its financial standing.
  • Analysts' average next Quarter EPS Estimate for ALKERMES PLC has witnessed a 25.73% change in the last 3 months, underscoring the dynamic nature of market sentiment towards the company's EPS prospects.
  • The quarterly earnings of ALKERMES PLC have shown a 3.0K% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • ALKERMES PLC shows accelerating EPS growth: when comparing the current Q2Q growth of 3.0K% to the previous year Q2Q growth of -85.71%, we see the growth rate improving.

Zooming in on the fundamentals.

At ChartMill, a crucial aspect of their analysis is the assignment of a Fundamental Rating to each stock. This rating, ranging from 0 to 10, is calculated daily by considering numerous fundamental indicators and properties.

Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 597 industry peers in the Biotechnology industry. ALKS has an excellent financial health rating, but there are some minor concerns on its profitability. ALKS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make ALKS suitable for value investing!

Our latest full fundamental report of ALKS contains the most current fundamental analsysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.


Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.



NASDAQ:ALKS (5/24/2024, 7:13:31 PM)

After market: 24.02 0 (0%)


+0.02 (+0.08%)


News Image3 days ago - InvestorPlace3 Biotech Stocks That Could Be Millionaire-Makers: May Edition

Investors should take a close look at these biotech stocks as they position themselves to provide high returns.

News Image11 days ago - Market News VideoALKS July 19th Options Begin Trading
News Image14 days ago - Alkermes plcAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and...

News Image20 days ago - ChartmillInvestors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.

ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.

News Image26 days ago - Alkermes plcAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to...

News Imagea month ago - InvestorPlaceALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Imagea month ago - Alkermes plcAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...

News Imagea month ago - Market News VideoFirst Week of June 21st Options Trading For Alkermes (ALKS)
News Imagea month ago - Alkermes plcAlkermes to Report First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...

News Image2 months ago - Market News VideoOversold Conditions For Alkermes (ALKS)
News Image2 months ago - Alkermes plcAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...

News Image2 months ago - Market News VideoNoteworthy Tuesday Option Activity: ALKS, DKNG, VRT
ALKS Links
Follow us for more